GSK Urges FDA Crackdown On Unsubstantiated Weight-Loss Claims
This article was originally published in The Tan Sheet
Executive Summary
FDA should take stricter enforcement action against marketers of weight-loss supplements who continue to use unsubstantiated product claims following receipt of a warning letter, according to GlaxoSmithKline Consumer Healthcare
You may also be interested in...
GSK Survey Finds Consumers “Confused” By Weight-Loss Drugs, Supplements
A survey commissioned by GlaxoSmithKline shows that many consumers are "confused" about the safety and regulation of dietary supplements for weight loss
GSK Sees Big Opportunity In OTC Diet Aids: Xenical Switch NDA Filed
GlaxoSmithKline filed an Rx-to-OTC switch application for Xenical (orlistat 60 mg) in June, the firm announced July 28
Supplement Substantiation Claims Guidance Aims For Clarity
FDA expects a new guidance detailing the boundaries of "competent and reliable scientific information" will enhance consumer confidence in supplement claims